Chemotherapy treatments are usually used for stage 2 and 3 cancer patients, and cancer during these stages undergoes partial hypoxia; as such, it can show resistance to anticancer drugs. Accordingly, the present inventors investigated the molecular mechanism of specific metabolic pathways in hypoxic cancerous tissues in which proliferation is active in order to develop an effective medicine for solid cancers (particularly colorectal cancers) that undergo hypoxia during the proliferation stage after the early stages. Through this investigation, the inventors developed a more fundamental and effective tumor treatment method. In solid cancers that grow quickly under conditions of hypoxia, energy and biomaterial are supplied through glycolysis. As a result, a great deal of lactate is produced and discharged outside of the cell. If this process is obstructed, acidification within the cell leads to the suspension of cell growth and subsequent cell death. The inventors successfully investigated the molecular action mechanism of this process and discovered that the HIF-1 transcription factor induced in hypoxia at lactic acid discharge increases the manifestation of MCT4 transporter, and that the proto-oncogene F(FBI-1) reduces this. On the other hand, NF-κB, which is activated in cancer cells under conditions of hypoxia, synthesizes with the proto-oncogene FB-I-1 promoter, which suppresses transcription, and, as such, reduces the manifestation of FBI-1 in in solid cancer in hypoxia, allowing the cancer cells to survive and increase. Therefore, the present invention was completed by discovering the new fact that propagation of cancer cells can be effectively obstructed through an increase in FBI-1 manifestation as well as an increase in the activation or manifestation of the cFBI-1 protein.